Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Accumulated Expenses (2019 - 2025)

Harmony Biosciences Holdings' Other Accumulated Expenses history spans 7 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 12.61% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 12.61%, while the annual FY2025 figure was $5.0 million, 12.61% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $5.0 million at Harmony Biosciences Holdings, up from $825000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $25.1 million in Q1 2024 and bottomed at $262000.0 in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $1.6 million (2022), against an average of $4.9 million.
  • The largest annual shift saw Other Accumulated Expenses soared 1260.05% in 2024 before it crashed 93.04% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.4 million in 2021, then grew by 19.41% to $1.6 million in 2022, then skyrocketed by 380.91% to $7.8 million in 2023, then decreased by 27.38% to $5.7 million in 2024, then decreased by 12.61% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Other Accumulated Expenses are $5.0 million (Q4 2025), $825000.0 (Q3 2025), and $1.6 million (Q2 2025).